Literature DB >> 12396610

Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection.

M M Addo1, X G Yu, E S Rosenberg, B D Walker, M Altfeld.   

Abstract

The HIV-1 regulatory proteins Tat and Rev and the accessory proteins Vpr, Vpu, and Vif are essential for viral replication, and their cytoplasmic production suggests that they should be processed for recognition by cytotoxic T lymphocytes. However, only limited data is available evaluating to which extent these proteins are targeted in natural infection and optimal cytotoxic T lymphocyte (CTL) epitopes within these proteins have not been defined. In this study, CTL responses against HIV-1 Tat, Rev, Vpr, Vpu, and Vif were analyzed in 70 HIV-1 infected individuals and 10 HIV-1 negative controls using overlapping peptides spanning the entire proteins. Peptide-specific interferon-gamma (IFN-gamma) production was measured by Elispot assay and flow-based intracellular cytokine quantification. HLA class I restriction and cytotoxic activity were confirmed after isolation of peptide-specific CD8+ T-cell lines. All regulatory and accessory proteins served as targets for HIV-1- specific CTL and multiple CTL epitopes were identified in functionally important regions of these proteins. In certain individuals HIV-1-specific CD8+ T-cell responses to these accessory and regulatory proteins contributed up to a third to the magnitude of the total HIV-1-specific CTL response. These data indicate that despite the small size of these proteins regulatory and accessory proteins are targeted by CTL in natural HIV-1 infection, and contribute importantly to the total HIV-1-specific CD8+ T-cell responses. These findings are relevant for the evaluation of the specificity and breadth of immune responses during acute and chronic#10; infection, and will be useful for the design and testing of candidate human immunodeficiency virus (HIV) vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12396610     DOI: 10.1089/104454902760330219

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  20 in total

Review 1.  Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience.

Authors:  Flavia Ferrantelli; Stefano Buttò; Aurelio Cafaro; Britta Wahren; Barbara Ensoli
Journal:  Springer Semin Immunopathol       Date:  2006-09-16

2.  HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV.

Authors:  Vijaya Madhavi; Bruce D Wines; Janaki Amin; Sean Emery; Ester Lopez; Anthony Kelleher; Rob J Center; P Mark Hogarth; Amy W Chung; Stephen J Kent; Ivan Stratov
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

3.  Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy.

Authors:  Jean-Pierre Routy; Mohamed-Rachid Boulassel; Bader Yassine-Diab; Charles Nicolette; Don Healey; Renu Jain; Claire Landry; Oleg Yegorov; Irina Tcherepanova; Tamara Monesmith; Lothar Finke; Rafick-Pierre Sékaly
Journal:  Clin Immunol       Date:  2009-11-04       Impact factor: 3.969

Review 4.  HIV-1 viral protein R (Vpr) and its interactions with host cell.

Authors:  Ge Li; Michael Bukrinsky; Richard Y Zhao
Journal:  Curr HIV Res       Date:  2009-03       Impact factor: 1.581

5.  Ratite oils promote keratinocyte cell growth and inhibit leukocyte activation.

Authors:  Darin C Bennett; Gigi Leung; Eddy Wang; Sam Ma; Blanche K K Lo; Kevin J McElwee; Kimberly M Cheng
Journal:  Poult Sci       Date:  2015-07-27       Impact factor: 3.352

6.  Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals.

Authors:  Ellen R Van Gulck; Guido Vanham; Leo Heyndrickx; Sandra Coppens; Katleen Vereecken; Derek Atkinson; Eric Florence; Ilse Kint; Zwi Nisan Berneman; Viggo Van Tendeloo
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

7.  Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.

Authors:  Andrew E Armitage; Koen Deforche; John J Welch; Kristel Van Laethem; Ricardo Camacho; Andrew Rambaut; Astrid K N Iversen
Journal:  J Virol       Date:  2014-08-27       Impact factor: 5.103

8.  Limited nucleotide changes in the Rev response element (RRE) during HIV-1 infection alter overall Rev-RRE activity and Rev multimerization.

Authors:  Emily A Sloan; Mary F Kearney; Laurie R Gray; Kathryn Anastos; Eric S Daar; Joseph Margolick; Frank Maldarelli; Marie-Louise Hammarskjold; David Rekosh
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

Review 9.  APOBEC3 Proteins in Viral Immunity.

Authors:  Spyridon Stavrou; Susan R Ross
Journal:  J Immunol       Date:  2015-11-15       Impact factor: 5.422

10.  The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90.

Authors:  Irina Tcherepanova; Aijing Starr; Brad Lackford; Melissa D Adams; Jean-Pierre Routy; Mohamed Rachid Boulassel; David Calderhead; Don Healey; Charles Nicolette
Journal:  PLoS One       Date:  2009-06-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.